S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

$27.83
+0.58 (+2.13%)
(As of 04/19/2024 ET)
Today's Range
$27.26
$27.97
50-Day Range
$26.15
$29.24
52-Week Range
$25.69
$77.14
Volume
331,952 shs
Average Volume
373,718 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.20

Omnicell MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
51.6% Upside
$42.20 Price Target
Short Interest
Bearish
5.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Omnicell in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
300.00%
From $0.09 to $0.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

597th out of 908 stocks

Electronic Computers Industry

4th out of 4 stocks

OMCL stock logo

About Omnicell Stock (NASDAQ:OMCL)

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

OMCL Stock Price History

OMCL Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Omnicell Announces XT Amplify
Omnicell (NASDAQ:OMCL) Shares Down 7%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Reasons for the Decline of Omnicell (OMCL)
Omnicell Is Building A Strong Moat
OMCL Dec 2024 30.000 call
Q4 2023 Omnicell Inc Earnings Call
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
Omnicell Q4 2023 Earnings Preview
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electronic computers
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,650
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$42.20
High Stock Price Target
$75.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+51.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-20,370,000.00
Pretax Margin
-1.75%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Cash Flow
$3.21 per share
Book Value
$26.15 per share

Miscellaneous

Free Float
44,711,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
0.76

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


OMCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price target for 2024?

6 equities research analysts have issued 12-month price targets for Omnicell's stock. Their OMCL share price targets range from $26.00 to $75.00. On average, they anticipate the company's share price to reach $42.20 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2024?

Omnicell's stock was trading at $37.63 at the start of the year. Since then, OMCL stock has decreased by 26.0% and is now trading at $27.83.
View the best growth stocks for 2024 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OMCL earnings forecast
.

How can I listen to Omnicell's earnings call?

Omnicell will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, February, 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The business had revenue of $258.85 million for the quarter, compared to analysts' expectations of $256 million. Omnicell had a positive trailing twelve-month return on equity of 3.43% and a negative net margin of 1.78%.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of -0.100--0.100 for the period, compared to the consensus estimate of 0.310. The company issued revenue guidance of $232.0 million-$242.0 million, compared to the consensus revenue estimate of $262.4 million.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a number of institutional and retail investors. Top institutional investors include Tributary Capital Management LLC (0.69%), Diversified Trust Co (0.03%) and Counterpoint Mutual Funds LLC (0.02%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
This page (NASDAQ:OMCL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners